Pilot Trial of CRLX101 in the Treatment of Patients With Advanced HER-2 Negative Gastric, Gastroesophageal, or Esophageal Squamous or Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2016
At a glance
- Drugs Camptothecin (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Pharmacokinetics
- 23 Mar 2016 Results from this trial have been published in the Proceedings of the National Academy of Sciences (PNAS), according to a Cerulean Pharma media release.
- 23 Mar 2016 Results published in a Cerulean media release.
- 09 Nov 2015 Data was presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, according to a Cerulean Pharma media release.